当前位置: X-MOL 学术Nat. Rev. Endocrinol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Cardiovascular endocrinology: Is ANGPTL3 the next PCSK9?
Nature Reviews Endocrinology ( IF 31.0 ) Pub Date : 2017-07-14 , DOI: 10.1038/nrendo.2017.88
Kiran Musunuru , Sekar Kathiresan

Recent reports suggest that molecular therapies targeting ANGPTL3 and its encoded protein angiopoietin-like protein 3 have clinical potential comparable to therapies targeting PCSK9 and its encoded protein proprotein convertase subtilisin/kexin type 9. By mainly affecting triglyceride-rich lipoproteins, ANGPTL3 inhibition might prove complementary to LDL cholesterol lowering with PCSK9 blockade.

中文翻译:

心血管内分泌学:ANGPTL3是下一个PCSK9吗?

最近的报道表明,靶向ANGPTL3及其编码的蛋白血管生成素样蛋白3的分子疗法具有与靶向PCSK9及其编码的蛋白原蛋白转化酶枯草杆菌蛋白酶/ kexin 9型疗法相当的临床潜力。通过主要影响富含甘油三酸酯的脂蛋白,ANGPTL3抑制作用可能证明是相辅相成的通过PCSK9阻滞降低LDL胆固醇。
更新日期:2017-08-24
down
wechat
bug